Sign in or create an account to add this stock to your watchlist.
About Allos Therapeutics (NASDAQ:ALTH)
Allos Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of anti-cancer therapeutics. As of December 31, 2011, the Company focused on the development and commercialization of FOLOTYN (pralatrexate injection). FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. FOLOTYN targets the inhibition of dihydrofolate reductase (DHFR), an enzyme critical in the folate pathway, thereby interfering with deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) synthesis and triggering cancer cell death. FOLOTYN can be delivered as a single agent, for which the Company has approval for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), and can be used in combination therapy regimens. On September 5, 2012, Spectrum Pharmaceuticals, Inc. acquired Allos Therapeutics, Inc.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
EPS (Most Recent Fiscal Year)N/A
Return on EquityN/A
Return on AssetsN/A
Allos Therapeutics (NASDAQ:ALTH) Frequently Asked Questions
What is Allos Therapeutics' stock symbol?
Allos Therapeutics trades on the NASDAQ under the ticker symbol "ALTH."
Has Allos Therapeutics been receiving favorable news coverage?
News headlines about ALTH stock have been trending somewhat positive on Sunday, according to Accern Sentiment Analysis. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Allos Therapeutics earned a daily sentiment score of 0.24 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 47.10 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
How do I buy shares of Allos Therapeutics?
Shares of ALTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How can I contact Allos Therapeutics?
Allos Therapeutics' mailing address is 11080 Circle Point Rd Ste 200, WESTMINSTER, CO 80020-2778, United States. The biopharmaceutical company can be reached via phone at +1-303-4266262.
MarketBeat Community Rating for Allos Therapeutics (ALTH)MarketBeat's community ratings are surveys of what our community members think about Allos Therapeutics and other stocks. Vote "Outperform" if you believe ALTH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALTH will underperform the S&P 500 over the long term. You may vote once every thirty days.
Allos Therapeutics (NASDAQ:ALTH) Analyst Ratings History
(Data available from 5/27/2016 forward)
|Date||Brokerage||Action||Rating||Price Target||Impact on Share Price||Details|
Allos Therapeutics (NASDAQ:ALTH) Earnings History and Estimates Chart
Allos Therapeutics (NASDAQ ALTH) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Allos Therapeutics (NASDAQ:ALTH) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Allos Therapeutics (NASDAQ ALTH) Insider Trading and Institutional Ownership History
Allos Therapeutics (NASDAQ ALTH) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
Allos Therapeutics (NASDAQ ALTH) News Headlines
No headlines for this company have been tracked by MarketBeat.com
Allos Therapeutics (NASDAQ:ALTH) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Allos Therapeutics (NASDAQ:ALTH) Income Statement, Balance Sheet and Cash Flow Statement
Allos Therapeutics (NASDAQ ALTH) Stock Chart for Sunday, May, 27, 2018